Probiotics research by Lallemand Health Solutions, a privately owned Canadian company specialising in the development, production and marketing of yeast and bacteria, has been recognised at a leading industry event for the second year in a row.
Innovative research presented by Jenna Ries won a Scientific Frontiers poster award at the recent Probiota 2016 event, in Amsterdam1. The winning poster described the development of a new, rapid method to detect the occurrence of rare pathogens in probiotics, using cutting edge technology.
The proof of concept study presented is very promising and could constitute a first step towards quicker quality control assays in probiotic production. Such progress marks Lallemand Health Solutions commitment to R&D, not only to continuously document its strain's benefits and modes of action, but also to improve its production processes and quality control, to better answer its customer’s needs.
The work presented showed that thanks to the application of sensitive detection technologies (mini VIDAS® or Flow Cytometry) to probiotic samples, Salmonella detection could be realised in less than 22 hours, compared with several days using traditional microbiological methods.
Today, this very promising study is a proof of concept. Further work still needs to be done to develop methods for the detection of other pathogens (e.g. E. coli) and contaminants (e.g. yeasts and moulds), before potential industrial application.
Reference
1. Development of a Novel Method for Rapid Pathogen Detection in Probiotic Products. Jenna N. Ries, Camille Chiron, Thomas A. Tompkins and Pierre Burguière, Probiota 2016, Amsterdam, NL.
